Back to Search
Start Over
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
- Source :
- The Lancet Respiratory Medicine; 20230101, Issue: Preprints
- Publication Year :
- 2023
-
Abstract
- COVID-19 vaccines with alternative strain compositions are needed to provide broad protection against newly emergent SARS-CoV-2 variants of concern. This study aimed to describe the clinical efficacy and safety of a bivalent SARS-CoV-2 recombinant protein vaccine as a two-injection primary series during a period of circulation of the omicron (B.1.1.529) variant.
Details
- Language :
- English
- ISSN :
- 22132600 and 22132619
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- The Lancet Respiratory Medicine
- Publication Type :
- Periodical
- Accession number :
- ejs63976215
- Full Text :
- https://doi.org/10.1016/S2213-2600(23)00263-1